LALPATHLAB1,912.00

Dr. Lal Path Labs Ltd.

· Pharma & Health
₹ CrorePeersMETROPOLISVIJAYATHYROCARENATCOPHARMNEULANDLABNHCOHANCESAILIFEMcap ₹32,045 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Inventory Days (DIO)30.1627.3729.9729.97
Receivable Days (DSO)12.6913.0614.6214.62
Payable Days (DPO)150.88150.70123.31118.26
Cash Conversion Cycle (days)-108.03-110.27-78.72-73.67
Working Capital Turnover3.372.562.482.59
Asset Turnover0.910.910.880.88
Cash Conversion (CFO/Net Income)1.481.161.251.25
CFO/EBITDA0.880.820.810.81
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.